FMT holds potential for treating various diseases beyond C. difficile infection, but its regulation by the FDA is crucial due to concerns about long-term effects and unintentional disease transfer.
Keep Reading
Add A Comment
Trending
- Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and Ethnicity (National Comprehensive Cancer Network)
- Physician Fee Schedule 2027: What physicians need to know now (Medical Economics)
- Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer (Business Wire)
- What Happens to Independent Medicine When Private Equity Shows Up With a Checkbook (MedCity News)
- AGA launches AI-powered virtual assistant for gastroenterology and hepatology care (News Medical)
- AMSURG Acquires 5 Endoscopy Centers in North Carolina (ASC News)
- Hawaii mandates free follow-up colonoscopies, wipes $91M in medical debt (Becker’s Healthcare)
- Endo Tools Therapeutics Secures $23 million in Series C Financing to Advance The endomina® technology and Commercialization of New endomina EZFuse System (Endo Tools Therapeutics)
